Next-Generation Influenza Vaccines.
By M. Kanekiyo, Barney S. Graham. 2020
38 citations recorded by the source corpus.
Most currently used conventional influenza vaccines are based on 1940s technology. Advances in vaccine immunogen design and delivery emerging over the last decade promise new options for improving influenza vaccines. In addition, new technologies for immune profiling provide better-defined immune correlates of protection and precise surrogate biomarkers for vaccine evaluations. Major technological advances include single-cell analysis, high-throughput antibody discovery, next-generation sequencing of antibody gene transcripts, antibody ontogeny, structure-guided immunogen design, nanoparticle display, delivery and formulation options, and better adjuvants. In this review, we provide our prospective outlook for improved influenza vaccines in the foreseeable future.
Subfields: Epidemiology, Molecular Biology, Radiology, Nuclear Medicine and Imaging
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Molecular Biology
In Radiology, Nuclear Medicine and Imaging
Citations in the corpus
- Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2 (2020, positive): “Continued development of such technology platforms could lead to vaccines that prevent the next pandemic rather than respond to it (Kanekiyo et al., 2019a; Kanekiyo and Graham, 2020).”
- Elicitation of broadly protective immunity to influenza by multivalent hemagglutinin nanoparticle vaccines (2020, background): “Including HAs from non-circulating subtypes, such as H5N1 and H7N9, may yield pandemic preparedness vaccines that provide broad protection against known and unknown pandemic threats 12 .”